Signalling and transcriptional control involve precise programmes of gene activation and suppression necessary for cardiovascular physiology. Deep sequencing of DNA-bound transcription factors reveals a remarkable complexity of co-activators or co-repressors that serve to alter chromatin modification and regulate gene expression. The regulated complexes characterized by genome-wide mapping implicate the recruitment and exchange of proteins with specific enzymatic activities that include roles for histone acetylation and methylation in key developmental programmes of the heart. As for transcriptional changes in response to pathological stress, co-regulatory complexes are also differentially utilized to regulate genes in cardiac disease. Members of the histone deacetylase (HDAC) family catalyse the removal of acetyl groups from proteins whose pharmacological inhibition has profound effects preventing heart failure. HDACs interact with a complex co-regulatory network of transcription factors, chromatin-remodelling complexes, and specific histone modifiers to regulate gene expression in the heart. For example, the histone methyltransferase (HMT), enhancer of zeste homolog 2 (Ezh2), is regulated by HDAC inhibition and associated with pathological cardiac hypertrophy. The challenge now is to target the activity of enzymes involved in protein modification to prevent or reverse the expression of genes implicated with cardiac hypertrophy. In this review, we discuss the role of HDACs and HMTs with a focus on chromatin modification and gene function as well as the clinical treatment of heart failure.
Introduction
The mechanical force required for heart function is achieved by complex contractions of cardiac muscle fibres within the myocardium (heart muscle). As predominant constituents of heart muscle, cardiomyocytes are the primary determinants of cardiac contractility. During normal development, the heart achieves anatomical specialization by separation to four individual chambers, namely the left and right atria as well as the left and right ventricles. Chamber specification is tightly co-ordinated by temporal and spatial expression of cardiac transcription factors such as T-box transcription factor 5 (Tbx5), GATA-binding protein 4 (Gata4), Myocyte enhancer factor-2 (Mef2), Csx/Nkx2-5 (Cardiac-specific homeobox/NK2 homeobox 5), and heart and neural crest derivatives expressed (Hand). 1 -4 Precise regulation of myocardial transcription is critical for homeostatic control in adults, because cardiomyocytes reach terminal differentiation and lose their ability to divide shortly after birth. 5 Co-ordinated expression of genes is under the control of both the DNA-binding transcription factors and co-regulatory proteins that either remodel accessibility of nucleosomal DNA or even catalyse chemical modifications to histone proteins within the chromatin template. 6, 7 Histone methylation (e.g. H3K4me3) and acetylation (e.g. H3K9/14ac) are generally correlated with permissive gene transcription, whereas H3K27me3 and deacetylation correlate with gene suppression. 8 For example, Enhancer of zeste homolog 2 (Ezh2) and Pax transactivation domain-interacting protein (Ptip) are two HMT enzymes that work along transcription factors and cardiac-specific deletion of either factors affected cardiac homeostasis conferred by changes to histone methylation and gene expression. 9, 10 The expression of genes that code for proteins implicated in cardiac hypertrophy, such as b-MHC and Anp, were elevated in Ezh2 null mice, whereas the physiological role of Ptip is consistent with conduction defect and susceptibility to ventricular arrhythmias. 9, 10 Furthermore, a recent study has shown that de novo mutations in genes encoding HMT enzymes are likely to contribute severe congenital heart disease. 11 In addition to chemical modifications to chromatin, are structural and topological changes mediated by ATP-dependent chromatin-remodelling proteins such as the SWItch/ Sucrose NonFermentable (SWI/SNF) complex proteins implicated in heart development and disease. 12 -14 More recently, non-coding RNAs (ncRNA) are proposed to interact with chromatin to regulate transcription factor binding in the myocardium. 15, 16 For example, long ncRNAs (lncRNAs) such as the Braveheart, Fendrr, and primary-miR-208b ( pri-miR-208b) are thought to mediate gene expression changes by chromatin interaction in the heart. 17 -19 Taken together, these recent data underscore the significance of epigenetic mechanisms in regulating gene expression programmes in cardiac physiology and pathology. Throughout one's lifetime, the heart is subject to a variety of physiological demands such as exercise or pregnancy that often result in cardiomyocyte hypertrophy and enlargement of ventricles. In addition, pathological surroundings such as pressure overload (aortic valve stenosis and hypertension), myocardial infarction, myocarditis, and idiopathic dilated cardiomyopathy induce cardiac adaptations. 20, 21 Cardiovascular disease stimulates cardiomyocyte enlargement and ventricular wall thickening, referred to as cardiac hypertrophy. While an increase in both the physiological and pathological demands results in enlargement of cardiomyocyte size by hypertrophic growth, pathological cardiac hypertrophy is regarded as a maladaptive response leading to irreversible remodelling of the ventricular chambers and eventually heart failure. Pharmacological inhibition of hypertrophic cardiomyocyte growth has been a long-term therapeutic goal for the treatment of heart failure. 22 Several mechanistic insights into the biology of cardiac hypertrophy are apparent and the best characterized with respect to cardiomyocyte growth is the reestablishment of the foetal gene programme. 23 Often studied yet poorly understood, the phase of cardiac hypertrophy is followed by the induction of pro-fibrotic and pro-inflammatory pathways leading to formation of interstitial fibrosis within the myocardium with increased risk of cardiac morbidity and mortality. 24, 25 Pharmacological inhibition of outside-in signalling pathways involving G protein-coupled receptors such as b-adrenergic receptors, ion-channels such as L-type Ca 2+ and Na + /H + exchangers, as well as cytoplasmic protein kinases such as CaM kinase II are known to attenuate cardiac hypertrophy and heart failure. 26, 27 However, drugs targeting these molecules are often ineffective and inhibit pathways that are either redundant in cardiomyocytes or mediating compensatory changes. Recent studies have identified several enzymes that chemically modify histone proteins and non-histone proteins as key regulators of pathological gene expression in cardiac hypertrophy. 28, 29 In addition to ATP-dependent chromatin remodellers such as Brahma-related gene 1 (Brg1) and Parp, 13 histone protein tails are targeted by enzymes for chemical modifications such as acetylation and methylation in cardiac hypertrophy and heart failure. 30 -32 The functional bridge between chromatin modifiers and signalling mediators is established through transcription factors that either suppress or promote gene expression. 33 Mef2 and Gata4 interact with enzymes and are found in many protein complexes that modify histones involved in gene activation under pathological conditions. 34, 35 These data support diverse regulation of gene transcription by complex interactions involving transcription factors including co-regulatory determinants such as p300 and ATP-dependent chromatin-remodelling proteins. 28 We have recently shown that some histone-modifying enzymes such as Ezh2 participate in cardiac myosin heavy chain (MHC) gene regulation by interacting with lncRNA to the chromatin template. 16, 17 A better understanding of the complex regulatory interactions that involve changes in chromatin structure and function mediated by cardiac stress signals is likely to benefit identifying novel therapeutic targets.
Chromatin remodelling of the hypertrophic heart
Chromatin architecture and its modification in higher eukaryotes are central to nuclear processes that include gene regulation, DNA repair, and recombination as well as replication. 36 -38 Chromatin remodelling is governed by two major classes of enzymes: one that covalently modifies histone proteins and the other that uses energy driven by ATP hydrolysis to reposition nucleosomes. Consisting of a family of ATP-dependent chromatin-remodelling proteins, the SWI/SNF complex regulates transcription in the heart in concert with co-activator and co-repressor complexes. 39 The SWI/SNF complex comprises Brahma (Brm) or Brg1 ATPase, which is considered critical chromatinremodelling machinery for vertebrate heart formation. A recent study 39 revealed dosage-sensitive interdependence between Brg1 and cardiac transcription factors such as Gata4, Nkx2-5, and Tbx5. Specifically, Brg1 haploinsufficiency in mice heart reduced Tbx5/Gata4 binding to target gene promoters, suggesting that relative allelic balance between Brg1 and DNA-binding transcription factors was essential for precise gene expression in the heart. Recently, the interactions between Brg1 and the DNA-binding protein, Parp1 with chromatin, were implicated in the prototypical shift in cardiac MHC isoform expression in pathological cardiac hypertrophy. 13 Ventricular hypertrophy is characterized by changes in gene expression that include reactivation of Anp, Bnp, and b-MHC genes, which is the characteristic of foetal gene programme as well as the suppression of genes that code for proteins implicated in adult heart function. 23, 40 For example, a-MHC and Serca2a genes are expressed at high levels in healthy hearts while their expression is suppressed during cardiac hypertrophy. These genesuppressive events are regulated by SWI/SNF containing Brm/ Brg1-associated HDAC co-repressor complexes. 12, 13 It is thought that the interaction of Brm with the proximal promoters of Anp and Bnp serves to enhance gene expression, whereas recruitment of Brg1 to a-MHC promoter was associated with transcriptional suppression in models of cardiac hypertrophy. 12 How chromatin-remodelling complexes are regulated for binding at specific gene sites in response to hypertrophic stimuli still remains unclear. What is known is that the control of transcription not only involves the actions of transcription factors and DNA-binding proteins, but also histone-modifying proteins, which can function to modify chromatin structure to alter gene function. For instance, contextual association of chromatin factors with either histone acetyltransferase (HAT) or HDAC enzymes may determine the expression of cardiac genes. 30 For example, recent studies also show novel interactions for histone-modifying proteins such as Ezh2 and Asxl2 at MHC promoters. 10, 17, 41 While these data support a complex network of chromatin interactions underlying hypertrophic gene regulation, further studies are needed to address the role of histone and non-histone-modifying complexes that work together with SWI/SNF-remodelling proteins in the heart.
Post-translational histone acetylation
Almost all eukaryotes package their DNA around histones to form structured nucleosome units. 42 Histone tails are sites for covalent modification by proteins with enzymatic activities including HATs, HDACs, and HMTs as well as with other modifying complexes that serve to alter chromatin structure and gene function. 38 Some of the best-studied histone-modifying enzymes include HATs and HDACs, which are strongly implicated in gene expression changes associated with pathological cardiac hypertrophy. 29, 30 Histone acetylation neutralizes the positive charge of lysine residues, consequentially weakening the chargedependent association of histone proteins and DNA. Whereas H3K9/ 14ac is generally linked to permissive gene expression, histone deacetylation is often linked to chromatin condensation and transcriptional suppression. 38 The advent of massive parallel sequencing (ChIP-seq) has allowed the analysis of genome-wide changes, which has been critical in characterizing histone modifications as well as cis-acting regulatory sequences important for cardiomyocyte gene regulation. 43 -45 For example, transcription factors that associate with one another are likely to have similar regulatory roles, and the Creb-binding protein (Cbp) and p300 are two HATs that are found on activated genes and implicated in distinguishing chromatin modifications involved in gene regulation in the left and right ventricles of the heart. 46 Analysis of gene sequences enriched for acetylated histones also revealed binding of cardiac transcription factors, such as Srf and Gata4 most likely mediated in part by p300 acetyltransferase. 44, 46 The p300 null mouse died at E9 and E11 days of development with severe abnormalities of the heart. 47 Whereas, transgenic expression of p300 induces cardiac hypertrophy in the mouse, agonist-induced cardiac hypertrophy is blocked in p300 mutant phenotypes. 48, 49 The potential connection between p300 regulatory complex and the actions of cardiac signals has led to the identification of transcription factors such as Gata4, Mef2d, and MyoD, as well as Mef2c involvement with transcriptional programmes that result from signalling cues that control pathological gene expression in the heart. 35, 50, 51 With clear implications for regulatory proteins conferring specific transcriptional events, myocardial stress in the adult heart increases p300 activity and H3K9/14ac, both resulting in cardiac hypertrophy-associated gene activation. 52 Accordingly, inhibition of cyclindependent kinase-9, a key mediator of p300/Gata4 complex, attenuated phenylephrine-induced hypertrophy in primary rat cardiomyocytes. 53 The small-molecule natural product curcumin is a selective inhibitor of p300 that reduces cardiac hypertrophy-induced acetylation as well as the binding of p300 and Gata4 complexes at promoters. 54 As well as being recognized to inhibit p300/Cbp complexes, curcumin improves ventricular function when used with angiotensin-converting enzyme inhibitors in rodent models of myocardial infarction. 55 Further studies are needed to address the specific role of p300 inhibition in the control of cardiac hypertrophy, as well as the general role of HAT catalytic activity in pathological cardiac remodelling.
Histone deacetylation and cardiac gene expression
There is a fine balance between acetylation and deacetylation of histone and non-histone proteins, and tipping this balance by inhibiting HDAC enzymes has shown therapeutic potential in the heart. 29, 56 HDACs are responsible for a series of enzymatic activities that remove acetyl groups from the 1-N-acetyl-L-lysine residue of histone and regulators of transcription. As for the role of HDAC's in the heart, studies have shown that pharmacological inhibition as well as genetic knockout can attenuate the expression of genes implicated in pathological cardiac hypertrophy ( Figure 1) . 29, 57 Whereas deacetylation of histone tails is linked with transcriptional suppression, deacetylation of non-histone proteins often serves to activate target gene expression. 58, 59 HDACs are broadly classified into four groups according to their function and sequence similarity. 60 The catalytic activity of Class I, Class II, and Class IV HDACs is zinc-dependent, while Class III HDACs which are also known as sirtuins are nicotinamide adenine dinucleotide (NAD + ) dependent. 61 Class I enzymes comprise HDAC-1, -2, -3, and -8, and this group is localized to the nucleus. 62 Class II HDACs are further subdivided into Class IIa (HDAC-4, -5, -7, and -9) and Class IIb (HDAC-6 and -10). These subclasses can shuttle between the cytosol and nucleus of the heart, skeletal muscle, and brain tissue, and are linked with cardiac defects. 61 Class III HDACs (Sirt1-7) are a class of NAD + -dependent enzymes found in both nucleus and cytoplasm, while Class IV HDAC (HDAC-11) is structurally distinct from the other groups and also localized to the nucleus and cytoplasm. 62, 63 Under the current paradigm, Class I HDAC enzymes are considered mediators of cardiac hypertrophy, whereas Class II HDACs are generally regarded as anti-hypertrophic. 30, 64 As well as being recognized as altering chromatin structure by deacetylation, HDAC enzymes are also found to interact with transcription factors such as Mef2 and co-regulatory determinants that regulate the expression of genes implicated in cardiac hypertrophy and heart failure. 29, 30 The Class II HDACs are by far the best characterized in the heart. Mutant mice lacking Class IIa HDACs show increased expression of genes regulated by Mef2 resulting in cardiac hypertrophy, whereas transgenic expression of Class IIa HDACs prevented activation of Mef2 target genes and attenuated cardiac hypertrophy. 65, 66 Although these data suggest that inhibition of HDAC activity would increase the risk of cardiac hypertrophy, recent studies using pan-HDAC inhibitors in mouse models support a pro-hypertrophic role for HDACs in the heart resulting in attenuation of pathological cardiac hypertrophy. 17, 57, 67 As the HDAC family comprises lysine deacetylase proteins, it has been postulated that distinct HDAC classes could mediate pro-and antihypertrophic signalling within the stressed myocardium. For example, Class I HDAC inhibition was sufficient enough to block cardiac hypertrophy induced by angiotensin II infusion and transverse aortic Figure 1 HDAC inhibition attenuates the expression of genes that encode proteins implicated in cardiac hypertrophy. Ventricular remodelling of the hypertrophic heart is associated with distinct changes in gene expression. The expression of Anp, Bnp, and b-MHC genes are increased, whereas Serca2 and a-MHC genes are decreased. HDAC inhibition attenuates cardiac hypertrophy by restoring the expression of these genes.
constriction. 29, 57 It is thought that the pro-hypertrophic effects of Class I HDACs are of higher catalytic efficiency than the anti-hypertrophic role of Class II HDACs. Class-selective HDAC inhibition revealed stressresponsive roles for many HDAC enzymes and potential targets in cardiovascular system. for normal cellular function and operate in multiple cell types within the heart, understanding the precise molecular targets of individual HDAC isoforms is essential for better therapy without causing marked consequences in the clinic.
HDAC inhibition-current standing and future perspectives
The distinct class specificity and diverse substrate binding of HDAC enzymes confer versatility in mediating stress-responsive signalling cues. The functional importance of HDAC inhibition in pre-clinical experiments is clear, since Trichostatin A blocks cardiac hypertrophy mediated by transverse aortic banding and calcium signalling as well as b-adrenergic agonists such as isoproterenol. 57, 68, 79 Although attention has focused on signalling pathways involving Mef2 interaction with Class IIa HDACs, a key challenge in the field is explaining how HDAC inhibition reverses or blocks pathological cardiac hypertrophy. It is increasingly evident that several HDAC enzymes are deregulated in preclinical models of heart failure through altered expression or aberrant chromatin interaction. 80 Both HDAC1 and HDAC2 are required for normal embryonic development since mice null for these enzymes are embryonic lethal at Day 9.5. 81 Whereas Class I HDACs are required for pathological signalling in adult hearts, these results also suggest that they are developmentally critical and necessary to achieve homeostatic gene expression. 80 HDAC inhibition to reduce cardiomyocyte hypertrophy also affects non-muscle cells within the heart resulting in diverse inflammatory responses associated with toxicity. 82 As for the therapeutic potential of HDAC inhibitors in disease, not all efficacies are handled equally. The effectiveness of HDAC inhibitors relies on their capacity to precisely control signalling programmes and this is clearly shown in oncology whereby dose is designed for maximum tolerability. 83 However, optimized drug activity and efficacy in heart failure without the need for the highest tolerable dose is the goal. While the inhibition of HDAC enzymes is an attractive therapeutic target with early trial success in the treatment of chronic arthritis, confirmation of HDAC-directed therapies awaits pre-clinical testing for heart failure. 84, 85 Following the FDA approval of two HDAC inhibitors, vorinostat and romidepsin for the treatment of cutaneous T-cell lymphoma, several class-selective HDAC inhibitors to Class I, II, and IV are underway with potential therapeutic benefits in treating patients with cancer and heart failure. 86 Indeed, a recent study 87 using SAHA (suberoylanilide hydroxamic acid, vorinostat) showed effective attenuation of myocardial reperfusion injury in rabbits with comparable plasma SAHA levels as achieved in cancer patients. Clearly, these recent observations in preclinical settings confer significant knowledge to rapidly develop HDAC inhibition-based clinical trials pertaining to the treatment of human heart failure.
Post-translational histone methylation in cardiac pathology
Transcription is precisely regulated and under the control of signalling pathways that involve the binding of regulatory determinants along with a series of histone methyl-writing and -erasing enzymes in the heart.
9,88
During heart development, the activities of these protein complexes serve to alter chromatin structure and gene function by post-translational modification of histone tails. 89, 90 Recent studies have shown genome-wide histone methylation changes in the failing myocardium. 28 H3K4 methylation and regulate the expression of genes implicated in cardiovascular diseases. 9, 91 Methylation of H3K4 is often associated with gene expression, whereas addition of the methyl-moiety to H3K9 and H3K27 is linked with transcriptionally repressive chromatin conformations. 38 For example, H3K4me3 is indispensable for the expression of Kcnip2, a gene encoding Kv-channel-interacting protein 2 required for cardiac repolarization. 9 Expression of Kcnip2 is reduced under heart failing conditions and associated with reduced H3K4me3 at the promoter. In contrast, ischaemic reperfusion in mouse models induced the expression of the G9a HMT and concomitant H3K9me3 modification at the Sirt-1 promoter paralleling Sirt-1 transcriptional suppression. 92 As for the heart, methylation of H3K27 by the Ezh2 polycomb-group (PcG) HMT was shown to be essential for cardiomyocyte lineagespecification during mouse embryogenesis. 93 The null Ezh2 mutant in the heart exhibited overexpression of pro-hypertrophic genes such as Anp, Bnp, and b-MHC. 10 Epigenetic regulation of genes by histone methylation in the heart is further extended by observations that H3K36 methylation, a mark typically associated with transcriptional elongation, was found to be co-associated with DNA methylation linked to gene regulation in the failing human heart. 31 A key finding of the study was that DNA methylation and H3K36me3 modification regulate the expression of double homeobox 4 gene (Dux4) in the failing human heart. 31 Although Dux4 expression is linked to muscular dystrophy, its role in the heart remains uncharacterized. 94 These results suggest that diverse histone lysine methylating enzymes are required for proper myocardial function; however, such enzymes are often deregulated during cardiovascular pathology. While we are beginning to understand the changes in chromatin modification in cardiac disease, we still do not know the regulatory proteins that confer gene expression events. Table 2 provides a list of histone modifiers that target co-regulators of gene expression in cardiovascular disease. Contrary to long-held views that post-translational modifications of histone tails were irreversible, the discovery of lysine-specific demethylase, LSD1, highlighted the removal of methyl-groups from histone tails. 100 Distinct classes of enzymes that catalyse demethylation of histone tail residues are also important regulators of cardiac gene expression. Recent studies have shown that increased expression of the lysine specific demethylase, Jmjd2a promotes cardiac hypertrophy ( Table 2) . 88 Whereas the expression of the four-and-a-half LIM domain 1 (Fhl1) gene is suppressed by H3K9me3 in the healthy heart, Jmjd2a binds to the Fhl1 promoter causing H3K9 demethylation as well as increased Fhl1 gene expression in cardiac hypertrophy. 88 The overexpression of Fhl1 is thought to mediate cardiac hypertrophy. 101 
Lessons from Ezh2 knockout mouse models
Polycomb-group proteins are found to be associated with several regulatory complexes that promote chromatin modification and are best known for their role in maintaining gene silencing. 102 In mammals, two major regulatory complexes have been described, the polycomb repressive complexes, PRC1 and PRC2. 103 PcG-mediated gene silencing is conferred by intrinsic HMT activity; the PRC2 holoenzyme is a complex of HMTs that include Suz12 and Eed with either Ezh2 or Ezh1 required for H3K27me3 modification. 102, 103 In the adult mouse heart, the expression of genes implicated in cardiac hypertrophy such as Anp and b-MHC as well as pro-fibrotic genes such as Tgfb3 are suppressed by Ezh2-mediated H3K27me3 modification. 10, 93, 104 Since chromatin modification exerts fundamental roles in transcriptional silencing, Ezh2 null mice show increased cardiomyocyte growth. These mutant mice have elevated expression of pro-fibrotic genes such as Tgfb3, Spp1, and Postn. 10 As for its role during development, Ezh2 expression is observed as early as E9.5 days in the heart indicating cardiac lineage-specification during embryogenesis. 10 Whereas cardiacspecific Ezh2 deletion in adult hearts promotes cardiac hypertrophy, its inactivation in cardiac progenitors confers severe heart malformations in later stages of development. 10, 104 Taken together, these experimental studies suggest an intrinsic role for Ezh2 in the developing heart.
Interplay between histone acetylation and methylation in the control of gene expression
The regulation of gene expression involves the co-ordinated actions of transcriptional machinery and regulatory determinants, which can function as either activators or repressors at gene promoters. These regulatory components involved in gene transcription include proteins with enzymatic activities for histone tail modification, including methylation. For example, embryonic stem cell differentiation is associated with a loss of H3K27me3 at enhancers and a gain in H3K27ac. 105 While H3K9/14ac
is associated with gene transcription, this also includes H3K4me3. 106, 107 Recent studies have shown the importance of histone methylation mediating the recruitment of HAT enzymes such as NuA3, which confers histone acetylation. 108, 109 While recent reports clearly show a better understanding of interpreting histone lysine modification in the context of active gene transcription, 110 studies from our laboratory indicate co-association of H3K4me3 and H3K9/14ac in regulating MHC gene expression in cardiac hypertrophy. 17 Combinatorial interactions between HMT, HAT, and HDAC enzymes are critical for robust gene regulation. 111 For example, suppression of gene activity requires co-ordinated actions of enzymes with lysine deacetylase as well as methyltransferase activity. 112, 113 Promyogenic activation by calcium/ calmodulin-dependent kinase (CaMK) mediates the exchange of Mef2 -Suv39h1 co-repressor complex with co-activators such as p300 and concomitant activation of genes critical for muscle differentiation. 112 Furthermore, the importance of H3K4me3 is also observed in models of cardiac hypertrophy; for example, pressure-overload-induced activation of Anp and Bnp genes are mediated by dissociation of Mef2 and HDAC4 complex as well as demethylation of lysine residues by the Jmjd1/2 complex. 73 Indeed, emerging evidence suggests that gene expression changes mediated by pathological cardiac hypertrophy involve Ezh2 and HDAC, which can be attenuated by HDAC inhibition. 17 As such, chromatin modifications conferred by histone/protein acetyltransferase and methyltransferase enzymes serve as important regulatory determinants of gene transcription in the heart.
Complexity of MHC gene regulation
The MHC protein is a fundamental component of the contractile machinery in the heart. Human a-and b-MHC genes are located in tandem and extend over 51 kb on chromosome 14 separated by unique regulatory-intergenic sequence. 114 Both MHC proteins vary in ATPase activity with a-MHC exhibiting three times faster ATPase activity than the b-MHC isoform. 115 Interestingly, these genes are reciprocally expressed not only in heart development but also in health and disease through complex interactions of transcriptional proteins ( Figure 2 ). Whereas expression of the b-MHC isoform predominates during myocardial development, the expression of a-MHC is highest later in life. Pathological stress inducing cardiac hypertrophy in mice elevates the expression of b-MHC gene and concomitant suppression of a-MHC. 116 In a similar fashion, failing human hearts show reduced a-MHC expression and dysfunctional myocardial contractility. 117, 118 ncRNA exerts an equally fundamental role in the regulation of gene expression as coding RNA. 16 Regulation of MHC gene transcription can work in several ways. First, the 4.5-kb intergenic sequence comprises a bi-directional promoter (bdP) coding antisense (AS) b-MHC transcript. 119, 120 This intergenic bdP has binding sites for Gata4 and regulators of transcription such as HDACs (HDAC2 and HDAC9), ATP-dependent chromatin-remodelling machinery (Brg1), as well as HMT enzymes such as Ezh2 (Figure 2) . 10, 12, 13 Cardiac-specific inactivation of Ezh2 in mice is associated with increased b-MHC and reduced a-MHC gene expression and cardiac hypertrophy. Consistent with a role for Ezh2 in cardiac homeostasis, the reactivation of Anp and Bnp genes in Ezh2 knockout mice is associated with reduced H3K27me3. 10 In favour of strong epigenetic mode of regulation, several DNase hypersensitive sites (DHS) have been mapped within the bdP, correlate with MHC expression during heart development, and are associated with MHC gene expression in adult hearts; however, the role of DHS in disease remains undetermined. 121, 122 Recent studies have shown that chromatin content as well as specific co-regulatory complexes serve to integrate ncRNAs to distinct transcriptional responses in the hypertrophied heart. 17 pri-miR-208b, a lncRNA, interacts with the intergenic sequence of the bdP implicated in the recruitment and binding of Ezh2 that ultimately suppress AS b-MHC and a-MHC gene expression. It is currently thought that Ezh2 binding at specific gene promoters may be regulated by lncRNAs such as the antisense RNAs and pri-miR-208b. 16 While we are beginning to understand how the MHC transcriptional switch is regulated by lncRNAs, we still do not know other target genes that localize Ezh2 for chromatin interaction in the heart. 
Concluding remarks
The characterization of transcriptional regulators associated with chromatin modification in the heart offers potential for therapy in cardiac disease. Recent studies of the transcriptional changes in the myocardium indicate specific regulatory enzymes and chromatin modifications that implicate gene expression changes in the failing heart. For example, the therapeutic potential for HDAC inhibitors in pre-clinical studies indicates efficacy, while further assessment is required of isoform-selective HDAC inhibitors targeting the myocardium. While most mechanistic insights have come from pre-clinical studies, the biggest challenge in this area is to develop therapeutic approaches in man. With epigenetic therapy gaining momentum, recent examples of innovative approaches and strategies have been reported for regulators of transcription. One of these is the pharmacological inhibition of Ezh2. 123, 124 Overexpression of Ezh2 and H3K27me3 are a hallmark of tumorigenesis, 125 -128 and the identification of Ezh2-activating point mutations implicated in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma suggests Ezh2 inhibition as a novel therapeutic strategy for these mutations. 124 Pharmacological inhibition of Ezh2 by small-molecule compounds such as GSK126 124 and EPZ005687 123 reduced H3K27me3 and activated PRC-silenced genes, which inhibited tumour growth. 123, 124 Similarly, DOT1L has been linked to the regulation of Dystrophin transcription in the mouse heart and thought to play a critical role in human idiopathic dilated cardiomyopathy. 99 DOT1L is a H3K79 methyltransferase associated with leukemogenesis and is implicated in regulating gene expression in mixed lineage leukaemia (MLL). Recently, a small-molecule inhibitor of DOT1L has been shown to reduce H3K79 methylation and transcription of genes associated with MLL disease. 129 The DOT1L inhibitor EPZ-5676 and the Ezh2 inhibitor EPZ-6438 have advanced to Phase I clinical trials in the treatment of cancer. 130, 131 In addition, while these studies demonstrate selective enzyme inhibition in lymphoma, understanding precise functions of these enzymes in the heart is of great significance. As for the role of Ezh2 in the heart, it seems likely that the interactions with histone and non-histone proteins mediated by lncRNA mechanisms regulate gene expression changes implicated in pathological cardiac hypertrophy. Cardiac remodelling and chromatin modifications
